Furthermore, analysis with the cBioPortal online tool revealed that though the average methylation levels of CDKN1C in AML patients with a poor prognosis had no significant differences versus those patients with a favorable prognosis from the TCGA database, low expression levels of CDKN1C were unfavorable prognostic factors in AML, indicating the potential of CDKN1C as a prognostic indicator (Supplementary Fig. S8C–E). Here, CDKN1C is linked to acute myeloid leukemia.